Indiana university's school of medicine, Private university in Evanston, Illinois

New York, Aug 30 Prior exposure to SARS-CoV-2, the virus causing Covid-19, neither guarantees a high level of antibodies nor immunity to re-infection as thought earlier, finds a study emphasising the need to get vaccinated against the deadly infectious disease.The study, led by researchers from the Northwestern University in the US, shows that two months after the second Pfizer/Moderna vaccination, antibody response decreases 20 per cent in adults with prior cases of Covid-19.It added that prior exposure to SARS-CoV-2 does not guarantee a robust antibody response to the first vaccine dose. This directly contradicts the assumption that contracting Covid will naturally make someone immune to re-infection.The findings, published in the journal Scientific Reports, further supports vaccination (and two doses), even for people who have contracted the virus previously."Many people, and many doctors, are assuming that any prior exposure to SARS-CoV-2 will confer immunity to re-infection. Based on this logic, some people with prior exposure don't think they need to get vaccinated. Or if they do get vaccinated, they think that they only need the first dose of the two-dose Pfizer/Moderna vaccines," said Thomas McDade, Professor of Anthropology in the Weinberg College of Arts and Sciences and a faculty fellow with the University's Institute for Policy Research."Our study shows that prior exposure to SARS-CoV-2 does not guarantee a high level of antibodies, nor does it guarantee a robust antibody response to the first vaccine dose. For people who had mild or asymptomatic infections, their antibody response to vaccination is essentially the same as it is for people who have not been previously exposed," he added.For the study, the team tested blood samples from adults who had contracted Covid to measure how long the immunity benefits of Pfizer and Moderna vaccines last and how well they protect from newer variants.When the team tested blood samples from participants collected about three weeks after their second vaccine dose, the average level of inhibition was 98 per cent, indicating a very high level of neutralising antibodies.The scientists tested emerging variants B.1.1351 (Beta), B.1.1.7 (Alpha) and P.1 (Gamma) and found the level of inhibition to viral variants was significantly lower, ranging from 67 per cent to 92 per cent.They also found that antibody response declined after two months by about 20 per cent, and that the antibody response to vaccination varied based on history of prior infection.Further, individuals with clinically confirmed cases of Covid-19 and multiple symptoms also showed a higher level of response than those who tested positive but had mild symptoms or were asymptomatic.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Indiana University's School Of MedicineFOLLOW

Indiana university's school of medicine, Latest News

New York, March 2 A study on rhesus macaques by a team of US researchers showed that SARS-CoV-2, ... ...

The Northwestern Medicine scientists have found that in order to treat ALS, you need to target the brain, not just the spine. ...

Beijing, Nov 17 Guardrails were invoked at a vaunted summit between US President Joe Biden and Chinese leader ... ...

Practice makes perfect, but sleep helps, too. Learning and executing a new motor skill can be enhanced if you can get additional memory processing during sleep, according to a recent study led by researchers at Northwestern University. ...

According to the findings of new research, practice makes one perfect, but sleep helps, too. Learning and executing a new motor skill can be enhanced if a person can get additional memory processing during sleep. ...

New York, Sep 30 Women who menstruate experienced irregularities in their menstrual cycle because of increased stress during ... ...

A new study has shown that two months after the second Pfizer/Moderna vaccination, antibody response decreases 20 per cent in adults with prior cases of COVID-19. The study also tested how well current vaccines resist emerging variants. ...

New York, Aug 30 Prior exposure to SARS-CoV-2, the virus causing Covid-19, neither guarantees a high level of ... ...